Akers Biosciences, Inc. Notice of Third Quarter Results (5123W)
November 10 2014 - 7:00AM
UK Regulatory
TIDMAKR
RNS Number : 5123W
Akers Biosciences, Inc.
10 November 2014
10 November 2014
Akers Biosciences, Inc.
Notice of Third Quarter Results
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "ABI"), a leading designer and manufacturer of rapid
diagnostic screening and testing products, will hold a conference
call on Thursday, November 13, 2014, at 10:30 a.m. ET (3:30 p.m.
GMT) following the publication the same day of its results for the
third quarter and nine months ended September 30, 2014.
Akers Biosciences' Co-Founder and Executive Chairman, Raymond F.
Akers, Jr. PhD, and Vice President of Finance, Gary Rauch, will
host the call and be available during the question-and-answer
session.
To participate in the call, please dial 1-(913)-312-9330
approximately 10 minutes prior to the scheduled start time.
Interested parties can also listen via a live Internet webcast,
which can be found via the Company's website at
http://ir.akersbiosciences.com/events.cfm, or alternately at
http://public.viavid.com/index.php?id=111901. The Conference ID
is 7992989.
A replay of the call will be available for two weeks from 1:30
p.m. ET (6:30 p.m. GMT) on November 13, 2014, until 11:59 p.m. ET
(4:59 a.m. GMT) on November 27, 2014. The number for the replay is
1-(858)-384-5517; the passcode for the replay is 7992989. In
addition, a recording of the call will be available via the
Company's website at http://www.akersbiosciences.com.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found on our website at www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Raymond F. Akers, Jr. PhD
Executive Chairman
Akers Biosciences, Inc.
Tel. +1 856 848 8698
Twitter. @AkersBio
Jon Cunningham
RedChip Companies, Inc. (US Investor Relations)
Tel. +1 407 644 4256 x107
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
finnCap (Nomad and Broker)
Tel. +44 (0)20 7220 0500
Ben Simons / Alexandra Roper
Vigo Communications (UK Investor Relations)
Tel. +44 (0)20 7016 9570
akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORUGGUAGUPCGAM
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024